CA3103622C - Composes 2,3-dihydrofuro[2,3-b] pyridine - Google Patents

Composes 2,3-dihydrofuro[2,3-b] pyridine Download PDF

Info

Publication number
CA3103622C
CA3103622C CA3103622A CA3103622A CA3103622C CA 3103622 C CA3103622 C CA 3103622C CA 3103622 A CA3103622 A CA 3103622A CA 3103622 A CA3103622 A CA 3103622A CA 3103622 C CA3103622 C CA 3103622C
Authority
CA
Canada
Prior art keywords
dihydrofuro
mixture
compound
pharmaceutically acceptable
scheme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3103622A
Other languages
English (en)
Other versions
CA3103622A1 (fr
Inventor
Nicolas Jacques Francois Dreyfus
Andrew Faller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3103622A1 publication Critical patent/CA3103622A1/fr
Application granted granted Critical
Publication of CA3103622C publication Critical patent/CA3103622C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21B—ROLLING OF METAL
    • B21B3/00—Rolling materials of special alloys so far as the composition of the alloy requires or permits special rolling methods or sequences ; Rolling of aluminium, copper, zinc or other non-ferrous metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21B—ROLLING OF METAL
    • B21B2261/00—Product parameters
    • B21B2261/20—Temperature
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21B—ROLLING OF METAL
    • B21B2265/00—Forming parameters
    • B21B2265/12—Rolling load or rolling pressure; roll force

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule I: dans lequel R représente H ou F; ou un sel pharmaceutiquement acceptable de celui-ci, et l'utilisation de composés de formule I pour le traitement de maladies neurodégénératives, telles que la maladie d'Alzheimer.
CA3103622A 2018-06-22 2019-06-14 Composes 2,3-dihydrofuro[2,3-b] pyridine Active CA3103622C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688434P 2018-06-22 2018-06-22
US62/688,434 2018-06-22
PCT/US2019/037232 WO2019245907A1 (fr) 2018-06-22 2019-06-14 Composés 2,3-dihydrofuro[2,3-b] pyridine

Publications (2)

Publication Number Publication Date
CA3103622A1 CA3103622A1 (fr) 2019-12-26
CA3103622C true CA3103622C (fr) 2023-04-18

Family

ID=66589915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103622A Active CA3103622C (fr) 2018-06-22 2019-06-14 Composes 2,3-dihydrofuro[2,3-b] pyridine

Country Status (8)

Country Link
US (1) US11214576B2 (fr)
EP (1) EP3810275B1 (fr)
JP (1) JP7026828B2 (fr)
CN (1) CN112312969B (fr)
CA (1) CA3103622C (fr)
ES (1) ES2967591T3 (fr)
TW (1) TWI726329B (fr)
WO (1) WO2019245907A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
WO2011140640A1 (fr) 2010-05-11 2011-11-17 Simon Fraser University Inhibiteurs sélectifs des glycosidases et leurs utilisations
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
RS58768B1 (sr) 2013-03-14 2019-06-28 Merck Patent Gmbh Inhibitori glikozidaze
KR102043337B1 (ko) 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
EP3389658B1 (fr) 2015-12-18 2020-11-25 Merck Sharp & Dohme Corp. Inhibiteurs de glycosidase et leurs utilisations
AU2017222964B2 (en) * 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
KR20180132629A (ko) 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物

Also Published As

Publication number Publication date
CA3103622A1 (fr) 2019-12-26
JP7026828B2 (ja) 2022-02-28
ES2967591T3 (es) 2024-05-03
CN112312969A (zh) 2021-02-02
CN112312969B (zh) 2023-07-14
EP3810275A1 (fr) 2021-04-28
WO2019245907A1 (fr) 2019-12-26
US20210070766A1 (en) 2021-03-11
JP2021528428A (ja) 2021-10-21
TW202015681A (zh) 2020-05-01
US11214576B2 (en) 2022-01-04
EP3810275B1 (fr) 2023-10-04
TWI726329B (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
CN102482221B (zh) 作为katii抑制剂的双环和三环化合物
NZ245381A (en) Azaheterocyclylmethylchroman derivatives and pharmaceutical compositions
CN116969936A (zh) Bcl-2抑制剂
CN109890824B (zh) 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
JP7560511B2 (ja) ６－フルオロ－２－メチルベンゾ［ｄ］チアゾール－５－イル化合物
AU2017353315B2 (en) (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
CN107216327A (zh) 5型磷酸二酯酶抑制剂及其制备方法和用途
CA3103622C (fr) Composes 2,3-dihydrofuro[2,3-b] pyridine
JP6977038B2 (ja) Ｇｓｋ−３阻害剤
CN121219298A (zh) 噻吩并[3,2-b]吡啶衍生物
CN101870696A (zh) 具有多巴胺D2和5-HT2a双重活性的N-芳基哌嗪衍生物
TWI545120B (zh) ３，４－二氫異喹啉衍生物之製造方法及此等衍生物之製造中間體
HK1166980B (en) Bicyclic and tricyclic compounds as kat ii inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526